Kurs
-1,48%
Likviditet
4,33 MSEK
Prenumeration
Kalender
Tid* | ||
2025-08-27 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-19 | - | Årsstämma |
2025-05-07 | 08:30 | Kvartalsrapport 2025-Q1 |
2025-02-17 | 07:30 | Bokslutskommuniké 2024 |
2024-11-06 | - | Kvartalsrapport 2024-Q3 |
2024-10-23 | - | Extra Bolagsstämma 2024 |
2024-08-26 | - | Kvartalsrapport 2024-Q2 |
2024-05-17 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2024-05-16 | - | Årsstämma |
2024-05-07 | - | Kvartalsrapport 2024-Q1 |
2024-02-15 | - | Bokslutskommuniké 2023 |
2023-11-28 | - | Extra Bolagsstämma 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-17 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2023-05-16 | - | Årsstämma |
2023-04-28 | - | Kvartalsrapport 2023-Q1 |
2023-02-20 | - | Bokslutskommuniké 2022 |
2023-02-16 | - | Extra Bolagsstämma 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-07-15 | - | Kvartalsrapport 2022-Q2 |
2022-05-19 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2022-05-18 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-27 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2021-05-11 | - | Årsstämma |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-03-05 | - | Extra Bolagsstämma 2021 |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-11-06 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-07-02 | - | Extra Bolagsstämma 2020 |
2020-05-15 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2020-05-14 | - | Årsstämma |
2020-05-08 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-08 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-08-21 | - | Extra Bolagsstämma 2019 |
2019-05-09 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2019-05-08 | - | Årsstämma |
2019-05-08 | - | Kvartalsrapport 2019-Q1 |
2019-02-15 | - | Bokslutskommuniké 2018 |
2018-11-08 | - | Kvartalsrapport 2018-Q3 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-09 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2018-05-08 | - | Årsstämma |
2018-05-08 | - | Kvartalsrapport 2018-Q1 |
2018-03-05 | - | Extra Bolagsstämma 2018 |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-11-28 | - | Kvartalsrapport 2017-Q3 |
2017-09-15 | - | Extra Bolagsstämma 2017 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-05-23 | - | Årsstämma |
2017-05-23 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-11-22 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
2016-05-17 | - | Extra Bolagsstämma 2016 |
2016-04-28 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2016-04-27 | - | Årsstämma |
2016-04-27 | - | Kvartalsrapport 2016-Q1 |
2016-02-18 | - | Bokslutskommuniké 2015 |
2015-11-24 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-05-20 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2015-05-19 | - | Årsstämma |
2015-05-19 | - | Kvartalsrapport 2015-Q1 |
2015-02-25 | - | Bokslutskommuniké 2014 |
2014-11-27 | - | Kvartalsrapport 2014-Q3 |
2014-11-21 | - | Extra Bolagsstämma 2014 |
2014-08-21 | - | Kvartalsrapport 2014-Q2 |
2014-05-15 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2014-05-14 | - | Årsstämma |
2014-05-14 | - | Kvartalsrapport 2014-Q1 |
2014-02-24 | - | Bokslutskommuniké 2013 |
2013-11-27 | - | Kvartalsrapport 2013-Q3 |
2013-08-20 | - | Kvartalsrapport 2013-Q2 |
2013-05-16 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2013-05-15 | - | Årsstämma |
2013-05-15 | - | Kvartalsrapport 2013-Q1 |
2013-02-28 | - | Bokslutskommuniké 2012 |
2013-01-08 | - | Extra Bolagsstämma 2013 |
2012-11-21 | - | Kvartalsrapport 2012-Q3 |
2012-08-21 | - | Kvartalsrapport 2012-Q2 |
2012-05-24 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2012-05-23 | - | Årsstämma |
2012-05-23 | - | Kvartalsrapport 2012-Q1 |
2012-02-22 | - | Bokslutskommuniké 2011 |
2011-11-23 | - | Kvartalsrapport 2011-Q3 |
2011-08-23 | - | Kvartalsrapport 2011-Q2 |
2011-05-27 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2011-05-26 | - | Årsstämma |
2011-05-26 | - | Kvartalsrapport 2011-Q1 |
2011-02-16 | - | Bokslutskommuniké 2010 |
2010-11-24 | - | Kvartalsrapport 2010-Q3 |
2010-05-28 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2010-05-27 | - | Kvartalsrapport 2010-Q1 |
2009-11-25 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
The extraordinary general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the “Company”) was held on 23 October 2024, whereby the shareholders primarily resolved on the following matter. All resolutions were unanimous.
Resolution on the approval of the board of directors’ resolution on a directed share issue
In accordance with previously published information, the board of directors resolved 27 September 2024 on a directed issue of shares, subject to the subsequent approval of the extraordinary general meeting. The general meeting resolved today to approve the board of directors’ resolution on a directed issue of a maximum of 1,104,000 shares. The right to subscribe for new shares shall, with deviation from the shareholders’ pre-emption rights, belong to Adam Dahlberg and Sorin J. Brull.
The Company’s share capital will increase by a maximum of SEK 138,000 through a directed issue of a maximum of 1,104,000 shares. The subscription price for the shares in the new issue is SEK 6.20 per share. Subscription shall be made by cash payment or on a subscription list not later than 28 October 2024.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime’s TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime’s products are commercialized in over 30 countries including direct sales teams in US and Germany.
Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at senzime.com.